Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen

OncoImmunology

Volumn 1, Issue 3, 2012, Pages 263-270

  Beatty, Pamela ^a,b   Ranganathan, Sarangarajan ^b   Finn, Olivera J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Cancer vaccine; Colon cancer; Inflammation; Inflammatory bowel disease; MUC1

Indexed keywords

MUCIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC INFLAMMATION; COLITIS; COLITIS ASSOCIATES COLON CANCER; COLON CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TARGETING; GASTROINTESTINAL DYSPLASIA; INTESTINE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; VACCINATION; WILD TYPE;

EID: 84870242896     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.18950     Document Type: Article

References (26)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7; http://dx.doi.org/10.1038/nature01322
2. Feagins LA, Souza RF, Spechler SJ. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol 2009; 6: 297-305; http://dx.doi.org/10.1038/nrgastro.2009.44
3. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011; 140:1807-16; http://dx.doi.org/10.1053/j.gastro.2011.01.057
4. Finn OJ, Gantt KR, Lepisto AJ, Pejawar-Gaddy S, Xue J, Beatty PL. Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas. Immunol Res 2011; 50:261-8; http://dx.doi.org/10.1007/s12026-011-8214-1
5. Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004; 82:249-93; http://dx.doi.org/10.1016/S0065-2776(04)82006-6
6. Adsay NV, Merati K, Andea A, Sarkar F, Hruban RH, Wilentz RE, et al. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 andMUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol 2002; 15:1087-95; http://dx.doi.org/10.1097/01.MP.0000028647.98725.8B
7. Ajioka Y, Allison LJ, Jass JR. Significance of MUC1 and MUC2 mucin expression in colorectal cancer. J Clin Pathol 1996; 49:560-4; http://dx.doi.org/10.1136/jcp.49.7.560
8. Beatty PL, Narayanan S, Gariepy J, Ranganathan S, Finn OJ. Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer. Cancer Prev Res (Phila); 3:438-46.
9. Beatty PL, Plevy SE, Sepulveda AR, Finn OJ. Cutting edge: transgenic expression of human MUC1 in IL-102/2 mice accelerates inflammatory bowel disease and progression to colon cancer. J Immunol 2007; 179:735-9
10. Ho SB, Ewing SL, Montgomery CK, Kim YS. Altered mucin core peptide immunoreactivity in the colon polyp-carcinoma sequence. Oncol Res 1996; 8:53-61
11. Jerome KR, Kirk AD, Pecher G, Ferguson WW, Finn OJ. A survivor of breast cancer with immunity toMUC-1 mucin, and lactational mastitis. Cancer Immunol Immunother 1997; 43:355-60; http://dx.doi.org/10.1007/s002620050344
12. Kadayakkara DK, Beatty PL, Turner MS, Janjic JM, Ahrens ET, Finn OJ. Inflammation driven by overexpression of the hypoglycosylated abnormal mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis. Pancreas 2010; 39:510-5; http://dx.doi.org/10.1097/MPA.0b013e3181bd6501
13. Longman RJ, Poulsom R, Corfield AP, Warren BF, Wright NA, Thomas MG. Alterations in the composition of the supramucosal defense barrier in relation to disease severity of ulcerative colitis. J Histochem Cytochem 2006; 54:1335-48; http://dx.doi.org/10.1369/jhc.5A6904.2006
14. Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 1998; 58:315-21
15. Ishizaka ST, Hawkins LD. E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant. Expert Rev Vaccines 2007; 6:773-84; http://dx.doi.org/10.1586/14760584.6.5.773
16. Brokx RD, Revers L, Zhang Q, Yang S, Mal TK, Ikura M, et al. Nuclear magnetic resonance-based dissection of a glycosyltransferase specificity for the mucin MUC1 tandem repeat. Biochemistry 2003; 42:13817-25; http://dx.doi.org/10.1021/bi0353070
17. Schneck JP, Slansky JE, O'Herrin SM, Greten TF. Monitoring antigen-specific T cells using MHC-Ig dimers. Curr Protoc Immunol 2001; Chapter 17: Unit 17 2.
18. Andrianifahanana M, Moniaux N, Batra SK. Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases. Biochim Biophys Acta2006; 1765:189-222.
19. Li Y, Bharti A, Chen D, Gong J, Kufe D. Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol 1998; 18:7216-24
20. Pandey P, Kharbanda S, Kufe D. Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res 1995; 55:4000-3
21. Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, et al. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004; 5:163-75; http://dx.doi.org/10.1016/S1535-6108(04)00020-0
22. Yin L, Huang L, Kufe D. MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. J Biol Chem 2004; 279:45721-7; http://dx.doi.org/10.1074/jbc.M408027200
23. Gaemers IC, Vos HL, Volders HH, van der Valk SW, Hilkens J. A stat-responsive element in the promoter of the episialin/MUC1 gene is involved in its overexpression in carcinoma cells. J Biol Chem 2001; 276: 6191-9; http://dx.doi.org/10.1074/jbc.M009449200
24. Shirasaki H, Kanaizumi E, Watanabe K, Konno N, Sato J, Narita S, et al. Tumor necrosis factor increases MUC1 mRNA in cultured human nasal epithelial cells. Acta Otolaryngol 2003; 123:524-31; http://dx.doi.org/10.1080/00016480310001268
25. Carlos CA, Dong HF, Howard OM, Oppenheim JJ, Hanisch FG, Finn OJ. Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J Immunol 2005; 175:1628-35
26. Cascio S, Zhang L, Finn OJ. MUC1 expression in tumor cells regulates transcription of proinflammatory cytokines by forming a complex with NF-{kappa}B p65 and binding to cytokine promoters: importance of the extracellular domain. J Biol Chem 2011; 286:42248-56; http://dx.doi.org/10.1074/jbc.M111.297630